title: Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
abstract: Posterior retinopathy of prematurity (ROP) is unusual in its atypical features and its aggressive, rapidly progressive course. It is more difficult to recognize and to treat, with many of these eyes progressing to retinal detachment despite multiple treatments with laser or cryotherapy. The authors present a case of aggressive posterior ROP refractory to multiple laser treatment. This patient was successfully treated with intravitreal bevacizumab, but required repeat treatment 4 months later. The second injection with bevacizumab was followed by progression to retinal detachment requiring surgery. The patient remains stable after surgery.
authors.affiliation: Department of Ophthalmology, Bascom Palmer Eye Institute, Miami Miller School of Medicine, Miami, Florida, USA.
authors.forename: Kevin K
authors.initials: KK
authors.lastname: Suk
authors.forename: Audina M
authors.initials: AM
authors.lastname: Berrocal
authors.forename: Timothy G
authors.initials: TG
authors.lastname: Murray
authors.forename: Ryan
authors.initials: R
authors.lastname: Rich
authors.forename: James C
authors.initials: JC
authors.lastname: Major
authors.forename: Ditte
authors.initials: D
authors.lastname: Hess
authors.forename: Rose A
authors.initials: RA
authors.lastname: Johnson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D018450:Disease Progression; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D058449:Intravitreal Injections; D017075:Laser Coagulation; D054023:Lasers, Semiconductor / Q000627:therapeutic use; D056687:Off-Label Use; D012008:Recurrence; D012163:Retinal Detachment / Q000175:diagnosis*; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D012178:Retinopathy of Prematurity / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D019233:Retreatment; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab